Navigation Links
NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
Date:6/10/2008

SAN MATEO, Calif., June 10 /PRNewswire-FirstCall/ - NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today the publication of Phase 3 data of its lead product candidate, NGX-4010, in the journal Neurology. The paper, titled, "Controlled Trial in High-Concentration Capsaicin Patch for Treatment of Painful HIV Neuropathy," will appear in the June 10, 2008 edition. The topline results from the C107 study were presented in February 2006 by study investigator and lead author, Dr. David Simpson, Professor of Neurology and Director of Clinical Neurophysiology Laboratories and Neuro-AIDS Program at The Mount Sinai Medical Center.

The Phase 3 trial was a randomized, double blind, multicenter, controlled study involving 307 patients with painful HIV-associated distal sensory polyneuropathy (HIV-DSP) receiving a single application of NGX-4010, a high-concentration capsaicin patch. In this trial, the primary endpoint was achieved with a statistically significant reduction in pain over a 12-week period. The NGX-4010 application was well tolerated with the most common side effects being transient application site reactions.

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers significant advantages over other pain therapies. NeurogesX' marketing authorization application (MAA) to the European Medicines Agency (EMEA) was accepted for review in September 2007 and NeurogesX plans to file a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) in 2008 for PHN.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the expected benefits of NeurogesX' lead product candidate, NGX-4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010 and the advantages of NGX-4010 over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX The Ruth Group

Stephen Ghiglieri Investors / Media

(650) 358-3310 Stephanie Carrington / Jason Rando

sghiglieri@neurogesx.com (646) 536-7017 / 7025

scarrington@theruthgroup.com

jrando@theruthgroup.com


'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
3. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
4. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
5. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
6. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
7. ASPIRE Independent Review Board Announces 10 Ways to Protect Participants Rights in Clinical Drug Trials and Optimize Results From Research
8. Atrium Medical Corporation Announces First Implant of First-in-Man CINATRA(TM) Voclosporin Coated Coronary Stent
9. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
10. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
11. Anpath Group, Inc. Announces Addition of MRSA and VRE Claims for Its EnviroTru(R) Disinfectant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2017)... 30, 2017 DarioHealth Corp. (NASDAQ: DRIO), a leading global ... announced that it will be presenting at the 7th annual LD ... Erez Raphael , CEO, of DarioHealth will be giving the ... held on June 6th & 7th, 2017 at the Luxe Sunset ... / micro-cap space. About LD ...
(Date:5/26/2017)... 2017  Endo International plc (NASDAQ: ENDP ) ... will represent the Company in a fireside chat at Goldman ... June 13, 2017 at 10:40 a.m. PT / 1:40 p.m. ... Rancho Palos Verdes, CA. ... be available on the Company,s website at http://www.endo.com/investors/overview . ...
(Date:5/22/2017)... 2017  Lilac Corp, the company that sells ... of a new website . The website ... clinical study that showed surprising clearance of the ... individuals suffering from HPV warts, precancerous, or cancerous ... no other treatments that clear the virus. Specifically, ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... ... Flood Insurance offerings. With the Federal Emergency Management Agency’s (FEMA) recent update of ... United States. In 2012, the Biggert-Waters Act was enacted to reflect the actual ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... Ulster University, ... June, 2017 from 9 am to 3 pm to present to graduate students exciting ... is an original curriculum project led by The Health Improvement Service of the ...
(Date:6/23/2017)... ... 2017 , ... Jusino Insurance Services, a locally owned firm ... Chicago metropolitan area, is embarking on a charity drive in conjunction with the ... in 1897, Hephzibah Children’s Association is one of the oldest social services agencies ...
(Date:6/23/2017)... ... June 23, 2017 , ... Radabaugh & ... to families and business owners in North Central West Virginia, is embarking on ... to differently abled residents in the region. , The Stepping Stones organization offers ...
(Date:6/22/2017)... ... June 22, 2017 , ... Branches, Inc. has been partnering with The ... funding to support its programs focused on providing opportunity to low-income families and breaking ... by the Foundation of $15,000 to support its , Climb to College & Career ...
Breaking Medicine News(10 mins):